[go: up one dir, main page]

DE60323155D1 - Von transthyretin und zur hemmung von transthyretin-fehlfaltung - Google Patents

Von transthyretin und zur hemmung von transthyretin-fehlfaltung

Info

Publication number
DE60323155D1
DE60323155D1 DE60323155T DE60323155T DE60323155D1 DE 60323155 D1 DE60323155 D1 DE 60323155D1 DE 60323155 T DE60323155 T DE 60323155T DE 60323155 T DE60323155 T DE 60323155T DE 60323155 D1 DE60323155 D1 DE 60323155D1
Authority
DE
Germany
Prior art keywords
transthyretine
transthyretin
inhibiting
misfolding
misplold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60323155T
Other languages
English (en)
Inventor
Jeffrey W Kelly
Evan T Powers
Hossein Razavi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32685364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60323155(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Application granted granted Critical
Publication of DE60323155D1 publication Critical patent/DE60323155D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60323155T 2002-12-19 2003-12-19 Von transthyretin und zur hemmung von transthyretin-fehlfaltung Expired - Lifetime DE60323155D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43507902P 2002-12-19 2002-12-19
US46543503P 2003-04-24 2003-04-24
PCT/US2003/040567 WO2004056315A2 (en) 2002-12-19 2003-12-19 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding

Publications (1)

Publication Number Publication Date
DE60323155D1 true DE60323155D1 (de) 2008-10-02

Family

ID=32685364

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60323155T Expired - Lifetime DE60323155D1 (de) 2002-12-19 2003-12-19 Von transthyretin und zur hemmung von transthyretin-fehlfaltung
DE201212000007 Pending DE122012000007I1 (de) 2002-12-19 2012-01-17 Zusammenzetzungen und verfahren zur stabilisierungvon transthyretin und zur hemmung von transthyret infehlfaltung.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE201212000007 Pending DE122012000007I1 (de) 2002-12-19 2012-01-17 Zusammenzetzungen und verfahren zur stabilisierungvon transthyretin und zur hemmung von transthyret infehlfaltung.

Country Status (19)

Country Link
US (6) US7214695B2 (de)
EP (3) EP2325651B1 (de)
JP (3) JP4665076B2 (de)
KR (1) KR101089904B1 (de)
CN (2) CN101413143B (de)
AT (2) ATE524741T1 (de)
AU (2) AU2003303196C1 (de)
BE (1) BE2012C008I2 (de)
BR (1) BRPI0317463B8 (de)
CA (2) CA2510455C (de)
CY (2) CY1108467T1 (de)
DE (2) DE60323155D1 (de)
DK (2) DK1988397T3 (de)
ES (3) ES2373639T3 (de)
FR (1) FR12C0008I2 (de)
LU (1) LU91935I2 (de)
PT (2) PT1988397E (de)
SI (1) SI1587821T1 (de)
WO (1) WO2004056315A2 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06105459B2 (ja) * 1988-08-11 1994-12-21 日本電気株式会社 ベクトル処理装置
CA2510455C (en) * 2002-12-19 2013-03-12 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
ATE433746T1 (de) * 2004-03-12 2009-07-15 Biodel Inc Insulinzusammensetzungen mit verbesserter wirkstoffabsorption
WO2005112913A1 (en) 2004-05-20 2005-12-01 The Scripps Research Institute Transthyretin stabilization
PL1819354T3 (pl) * 2004-08-26 2011-12-30 Biocrine Ab Sposoby i związki do leczenia cukrzycy
EP1921916A2 (de) * 2005-08-11 2008-05-21 The Scripps Research Institute Genistein-hemmung von transthyretin-amyloidose
EP2074223A4 (de) * 2006-09-15 2010-03-10 Foldrx Pharmaceuticals Inc Testverfahren zum nachweis von proteinen im nativen zustand und zur identifizierung von die stabilität von proteinen im nativen zustand modulierenden verbindungen
WO2010054127A1 (en) * 2008-11-05 2010-05-14 Elan Pharmaceuticals, Inc. Methods and agents for stabilizing non-pathological amyloidogenic polypeptides
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
US20120101021A1 (en) 2009-02-06 2012-04-26 Surendra Sharma Compositions, formulations and methods of treating preeclampsia-type disorders of pregnancy
WO2011116123A1 (en) * 2010-03-19 2011-09-22 Irm Llc Tafamidis for the treatment of ophthalmic diseases
KR20130079353A (ko) 2010-04-21 2013-07-10 키에시 파르마슈티시 엣스. 피. 에이. 트랜스티레틴 아밀로이드증 치료용 1-(2-플루오로비페닐-4-일)-알킬 카복실산 유도체
US8877795B2 (en) 2010-05-07 2014-11-04 The Board Of Trustees Of The Leland Stanford Junior University Identification of stabilizers of multimeric proteins
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
CA2847293C (en) * 2011-09-16 2017-03-28 Richard Frederic Labaudiniere Solid forms of a transthyretin dissociation inhibitor
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
AU2013257742A1 (en) 2012-05-07 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9738631B2 (en) 2012-05-07 2017-08-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
NZ701832A (en) 2012-05-23 2016-08-26 Cellix Bio Private Ltd Compositions and methods for treatment of inflammatory bowel disease
EP2852569B1 (de) 2012-05-23 2020-10-14 Cellixbio Private Limited Zusammensetzungen und verfahren zur behandlung von multipler sklerose
CA2873104A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of mucositis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
SG11201407325YA (en) 2012-09-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammation and lipid disorders
US9169214B2 (en) * 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
US9790269B2 (en) 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
US10227301B2 (en) 2015-01-06 2019-03-12 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and pain
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3179857B1 (de) 2014-08-14 2021-09-08 Mamoun M. Alhamadsheh Konjugation von pharmazeutischen wirkstoffen mit transthyretinliganden durch anpassbare linker zur erhöhung der serumshalbwertszeit
ES2975633T3 (es) * 2014-09-08 2024-07-10 Pfizer Formas sólidas cristalinas de 6-carboxi-2-(3,5-diclorofenil)-benzoxazol para su uso como medicamento
NZ736131A (en) 2014-09-26 2019-04-26 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
CN107207403A (zh) 2014-09-29 2017-09-26 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的组合物和方法
CN107108535B (zh) 2014-10-27 2020-04-28 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的富马酸单甲酯与哌嗪或乙二胺的三组分盐
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN107344927A (zh) 2016-05-05 2017-11-14 苏州晶云药物科技有限公司 Tafamidis葡甲胺盐的晶型E及其制备方法和用途
CN106496014A (zh) * 2016-10-17 2017-03-15 河北美星化工有限公司 一种二氟尼柳的制备方法
EP4218784A3 (de) 2017-05-22 2023-09-13 National Hellenic Research Foundation Makrocyclische modulatoren von krankheitsassoziierter proteinfehlfaltung und aggregation
GB2571950A (en) 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
CN108558599B (zh) * 2018-03-29 2021-01-29 浦拉司科技（上海）有限责任公司 2-联苯基甲醇的合成工艺
US12268669B2 (en) 2018-12-20 2025-04-08 Pfizer Inc. Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
ES2991081T3 (es) 2019-04-11 2024-12-02 Inke Sa Procedimiento para preparar 2-(3,5-diclorofenil)-6-benzoxazolcarboxilato de 1-desoxi-1-metilamino-D-glucitol
EP4512399A2 (de) 2019-05-16 2025-02-26 Teva Pharmaceuticals International GmbH Feste formen von tafamidis und salze davon
CN110215740B (zh) * 2019-07-15 2021-05-04 大连医科大学 一种两性离子亲水前处理硅胶材料的制备方法
WO2021019448A1 (en) * 2019-08-01 2021-02-04 Honour (R&D) Process for the preparation of transthyretin dissociation inhibitor
WO2021093809A1 (zh) 2019-11-15 2021-05-20 苏州科睿思制药有限公司 他发米帝司的晶型及其制备方法和用途
JP2023507399A (ja) * 2019-12-20 2023-02-22 ファイザー アイルランド ファーマシューティカルズ ６－カルボキシベンゾオキサゾール誘導体を作製するための効率的なプロセス
WO2021152623A1 (en) * 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt
BR112022014635A2 (pt) 2020-01-28 2022-10-11 Protego Biopharma Inc Compostos, composições e métodos para estabilizar transtirretina e inibir mau dobramento de transtirretina
WO2022112919A1 (en) 2020-11-25 2022-06-02 Pfizer Inc. (aza)benzothiazolyl substituted pyrazole compounds
CN112683844A (zh) * 2020-12-07 2021-04-20 东华理工大学 一种振动对吲哚美辛-糖精共晶形成影响的研究方法
CN112858690B (zh) * 2021-01-21 2023-11-10 宁波职业技术学院 一种尿白蛋白/尿肌酐复合质控品及其制备方法
CN114907283B (zh) * 2021-02-07 2025-01-28 南京正大天晴制药有限公司 一种2-(3，5-二氯苯基)-苯并噁唑-6-羧酸的制备方法
EP4083027A1 (de) 2021-04-26 2022-11-02 Química Sintética, S.A. Festkörperform von tafamidis und verfahren zu deren herstellung
CN113372290A (zh) * 2021-05-21 2021-09-10 遵义医科大学 一种药物Tafamidis的合成方法
CN113321627B (zh) * 2021-06-06 2022-05-24 湖南第一师范学院 一种Tafamidis衍生物及其合成方法
EP4351541A2 (de) 2021-06-08 2024-04-17 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung oder prävention von erkrankungen im zusammenhang mit morbus stargardt und/oder retinal-bindendem protein 4 (rbp4)
WO2023020762A1 (en) 2021-08-16 2023-02-23 Synthon B.V. Crystalline forms of tafamidis nicotinamide adduct
JP2024541422A (ja) 2021-11-17 2024-11-08 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー タファミジスの固体状態の形態
CN114970600B (zh) * 2022-04-11 2024-07-26 昆明理工大学 基于粒化散布熵和优化kelm的滚动轴承故障诊断方法、装置
CN119585243A (zh) 2022-07-22 2025-03-07 白鸟制药株式会社 氯苯唑酸或其盐的制造方法
CN119604278A (zh) 2022-07-28 2025-03-11 辉瑞大药厂 氯苯唑酸药物组合物
US11970468B1 (en) 2023-10-23 2024-04-30 King Faisal University 2-(benzo[d]oxazol-2-yl)-N′-(3,5-dichlorobenzoyloxy)acetimidamide as an antimicrobial compound

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US435079A (en) 1890-08-26 Lock-nut for axles
DE602336C (de) 1933-03-09 1934-09-06 I G Farbenindustrie Akt Ges Verfahren zur Herstellung von Kuepenfarbstoffen der Anthrachinonreihe
US3551433A (en) * 1967-06-21 1970-12-29 Us Army Preparation of 4-phenyl-4-acyloxypiperidine
US3551443A (en) * 1968-10-30 1970-12-29 Ciba Ltd 2-phenylbenzoxazole derivatives
USRE29608E (en) * 1972-05-18 1978-04-11 Lilly Industries Limited Benzoxazole derivatives
DE2314238A1 (de) 1973-03-22 1974-09-26 Henkel & Cie Gmbh Neue 2-(tetrazol-5'-yl)-benzoxazole, deren herstellung sowie verwendung als entzuendungshemmer in kosmetischen praeparationen
US4025636A (en) * 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2-(Optionally substituted)phenyl-5 or 6-substituted benzoxazoles
US4025637A (en) * 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2,5 OR 2,6 Disubstituted benzoxazoles
DE2619547A1 (de) * 1976-05-04 1977-11-24 Dynamit Nobel Ag Verfahren zur herstellung von 2-aryl- benzoxazolen und 2-aryl-benzthiazolen
US4416892A (en) * 1981-04-23 1983-11-22 Lilly Industries Limited Method of treating hypersensitivity disease with benzoxazole derivatives
US5254692A (en) * 1990-04-06 1993-10-19 Bayer Aktiengesellschaft 2,6-dialkyl-4-(benzothiazol- or benzoxazol-7-yl)-1,4-dihydropyridines
DE4011106A1 (de) * 1990-04-06 1991-10-10 Bayer Ag Neue heterocyclisch substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5037842A (en) * 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
CA2051518A1 (en) 1990-10-01 1992-04-02 Robert J. Perry Synthesis of heterocyclic compounds
JP3021028B2 (ja) 1990-11-19 2000-03-15 株式会社日本化学工業所 アゾール型カチオン染料
CH681806A5 (de) 1991-03-19 1993-05-28 Ciba Geigy Ag
JPH0517458A (ja) 1991-07-04 1993-01-26 Idemitsu Kosan Co Ltd 芳香族化合物とその製造方法
US5354759A (en) * 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
JPH0673050A (ja) 1992-08-26 1994-03-15 Asahi Glass Co Ltd ヘテロ環化合物
JPH0673051A (ja) 1992-08-26 1994-03-15 Asahi Glass Co Ltd ベンズアゾール誘導体
GB9218334D0 (en) * 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
DE4304650A1 (de) 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
JPH06239849A (ja) 1993-02-16 1994-08-30 Canon Inc 光学活性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法及び表示装置
JP3243887B2 (ja) 1993-05-28 2002-01-07 三菱化学株式会社 有機電界発光素子
JPH0797379A (ja) 1993-09-06 1995-04-11 Canon Inc 液晶性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法および表示装置
US5441946A (en) * 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
US5552426A (en) * 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
US5837390A (en) * 1995-05-10 1998-11-17 Sony Corporation Metal complex, method for producing the same and optical device
JP3861930B2 (ja) 1995-12-15 2006-12-27 ソニー株式会社 金属複核錯体、その製造方法及び光学的素子
JPH09227576A (ja) 1996-02-23 1997-09-02 Sony Corp 金属複核錯体、その製造方法及び光学的素子
JP3760508B2 (ja) 1996-06-10 2006-03-29 東洋インキ製造株式会社 有機エレクトロルミネッセンス素子材料およびそれを用いた有機エレクトロルミネッセンス素子
AU3390297A (en) 1996-06-14 1998-01-07 Aaron Diamond Aids Research Center, The Uses of a chemokine receptor for inhibiting hiv-1 infection
AU5727798A (en) 1996-12-23 1998-07-17 Texas A & M University, The Anti-amyloidogenic agents
FR2767527B1 (fr) * 1997-08-25 1999-11-12 Pf Medicament Derives de piperazines indoliques, utiles comme medicaments et procede de preparation
GB9725782D0 (en) * 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
EP1053237B1 (de) * 1998-02-04 2003-07-02 The Board Of Regents, The University Of Texas System Hemmung der menschlichen telomerase durch g-quadruplex interaktionverbindung
US6107491A (en) * 1998-07-20 2000-08-22 Ciba Specialty Chemicals Corporation Polymerizable diketopyrrolopyrroles
GB9816654D0 (en) * 1998-07-30 1998-09-30 Zeneca Ltd Chemical compounds
JP2000100569A (ja) 1998-09-22 2000-04-07 Toray Ind Inc 発光素子
JP2001055332A (ja) 1999-06-07 2001-02-27 Saitama Daiichi Seiyaku Kk 芳香族アミジン誘導体類含有のイオントフォレ−シス用製剤
PL352285A1 (en) 1999-06-18 2003-08-11 Bayer Ag Phenoxy fluoropyrimidines
JP2001064205A (ja) 1999-06-25 2001-03-13 Dai Ichi Seiyaku Co Ltd 製剤組成物
JP2001064166A (ja) 1999-06-25 2001-03-13 Dai Ichi Seiyaku Co Ltd 貼付剤
US6420418B1 (en) * 1999-08-16 2002-07-16 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
GB9919673D0 (en) 1999-08-20 1999-10-20 Cancer Res Campaign Tech 2-Arlybenzazole compounds
JP2001226358A (ja) 1999-10-12 2001-08-21 Japan Tobacco Inc Ｌｐｌ活性増強剤
JP2001242165A (ja) 2000-02-25 2001-09-07 Dai Ichi Seiyaku Co Ltd 採血用試薬
AU2001252168B2 (en) 2000-03-16 2007-07-12 F. Hoffmann-La Roche Ag Carboxylic acid derivatives as ip antagonists
GB0007934D0 (en) 2000-03-31 2000-05-17 Darwin Discovery Ltd Chemical compounds
JP3945123B2 (ja) 2000-04-10 2007-07-18 三菱化学株式会社 有機電界発光素子
JP2001301329A (ja) 2000-04-20 2001-10-31 Mitsubishi Chemicals Corp 光学記録媒体
JP2002003368A (ja) 2000-06-23 2002-01-09 Saitama Daiichi Seiyaku Kk 経皮吸収又は経粘膜吸収用の製剤
US20020133019A1 (en) 2000-08-24 2002-09-19 Klunk William E. Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and vivo imaging and prevention of amyloid deposition
WO2002036553A2 (en) 2000-11-04 2002-05-10 Aventis Pharma Limited Substituted alkanoic acids
EP1341768A1 (de) 2000-12-07 2003-09-10 AstraZeneca AB Therapeutische benzimidazolverbindungen
US7045539B2 (en) 2000-12-22 2006-05-16 Astrazeneca Ab Therapeutic benzoxazole compounds
GB0118357D0 (en) 2001-07-27 2001-09-19 Syngenta Ltd Chemical compounds
WO2003020698A2 (en) 2001-09-06 2003-03-13 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
US6602619B2 (en) * 2001-10-19 2003-08-05 Lightronik Technology Inc. Organic EL device
CN100338040C (zh) * 2001-11-16 2007-09-19 日本化学医药株式会社 黄嘌呤氧化酶抑制化合物
EP1478631A1 (de) 2001-11-28 2004-11-24 AstraZeneca AB Therapeutische verbindungen
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
WO2003053359A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
AU2002360763A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
GB0205256D0 (en) 2002-03-06 2002-04-17 Oxford Glycosciences Uk Ltd Novel compounds
BR0308537A (pt) 2002-03-20 2005-02-09 Metabolex Inc Composto, composição, e métodos para tratar diabetes tipo 2 e hiperuricemia, para modular resistência a insulina e para aliviar hiperlipidemia em um indivìduo e agente de prodroga
UA79755C2 (en) 2002-04-16 2007-07-25 Bayer Pharmaceuticals Corp Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
GB0226822D0 (en) 2002-11-16 2002-12-24 Oxford Glycosciences Uk Ltd Novel compounds
CA2510455C (en) * 2002-12-19 2013-03-12 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
AU2004206796A1 (en) 2003-01-14 2004-08-05 Merck & Co., Inc. Geminally di-substituted NSAID derivatives as Abeta 42 lowering agents
JP2004250411A (ja) 2003-02-21 2004-09-09 Bf Kenkyusho:Kk アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
AR044503A1 (es) 2003-03-18 2005-09-14 Merck & Co Inc Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
CN1791580A (zh) 2003-03-24 2006-06-21 麦克公司 联芳基取代的6元杂环钠通道阻滞剂
JP2004302049A (ja) 2003-03-31 2004-10-28 Hodogaya Chem Co Ltd 感光性樹脂組成物
CN1798738A (zh) 2003-04-03 2006-07-05 麦克公司 作为钠通道阻滞剂的联芳基取代吡唑
EP1618099A4 (de) 2003-04-18 2008-07-16 Merck & Co Inc Biarylsubstituierte diazole, oxazole und imidazole als natriumkanalblocker
EP1620413A2 (de) 2003-04-30 2006-02-01 Cytokinetics, Inc. Verbindungen, zusammensetzungen und verfahren
WO2005112913A1 (en) * 2004-05-20 2005-12-01 The Scripps Research Institute Transthyretin stabilization

Also Published As

Publication number Publication date
AU2010201263B2 (en) 2012-12-20
US20070078186A1 (en) 2007-04-05
JP2006511612A (ja) 2006-04-06
KR20050090410A (ko) 2005-09-13
JP4665076B2 (ja) 2011-04-06
AU2010201263A1 (en) 2010-04-22
CN101413143B (zh) 2013-09-18
LU91935I9 (de) 2019-01-04
AU2010201263B8 (en) 2013-04-18
AU2003303196B2 (en) 2010-03-25
US20100120919A1 (en) 2010-05-13
EP2325651A2 (de) 2011-05-25
FR12C0008I2 (fr) 2013-01-11
EP1988397A1 (de) 2008-11-05
EP1988397B1 (de) 2011-09-14
CY1108467T1 (el) 2014-04-09
ATE524741T1 (de) 2011-09-15
CN100448852C (zh) 2009-01-07
US20060057644A1 (en) 2006-03-16
CA2510455A1 (en) 2004-07-08
EP1988397B8 (de) 2012-02-15
ES2312857T3 (es) 2009-03-01
JP5756151B2 (ja) 2015-07-29
US7560488B2 (en) 2009-07-14
AU2003303196C1 (en) 2021-03-25
CA2800237C (en) 2016-05-17
BR0317463A (pt) 2005-11-16
DE122012000007I1 (de) 2012-04-12
EP1587821B1 (de) 2008-08-20
US7214695B2 (en) 2007-05-08
PT1988397E (pt) 2011-12-02
US20040152140A1 (en) 2004-08-05
US20120065237A1 (en) 2012-03-15
US7214696B2 (en) 2007-05-08
AU2003303196A1 (en) 2004-07-14
PT1587821E (pt) 2008-09-23
FR12C0008I1 (de) 2012-03-30
CN101413143A (zh) 2009-04-22
EP2325651B1 (de) 2014-10-08
BRPI0317463B8 (pt) 2021-05-25
JP2010270134A (ja) 2010-12-02
AU2010201263A8 (en) 2013-04-18
ES2373639T3 (es) 2012-02-07
CA2800237A1 (en) 2004-07-08
SI1587821T1 (sl) 2009-02-28
ATE405840T1 (de) 2008-09-15
JP2013256521A (ja) 2013-12-26
US8168663B2 (en) 2012-05-01
EP2325651A3 (de) 2011-09-21
CA2510455C (en) 2013-03-12
WO2004056315A3 (en) 2005-08-11
CY2012005I1 (el) 2015-10-07
BRPI0317463B1 (pt) 2017-04-18
US8653119B2 (en) 2014-02-18
ES2524803T3 (es) 2014-12-12
CN1747965A (zh) 2006-03-15
US20140134753A1 (en) 2014-05-15
CY2012005I2 (el) 2015-10-07
LU91935I2 (fr) 2012-03-26
DK1587821T3 (da) 2008-11-10
BE2012C008I2 (de) 2023-03-07
WO2004056315A2 (en) 2004-07-08
EP1587821A2 (de) 2005-10-26
DK1988397T3 (da) 2011-12-12
WO2004056315A8 (en) 2005-12-08
KR101089904B1 (ko) 2011-12-05
EP1587821A4 (de) 2007-05-09

Similar Documents

Publication Publication Date Title
DE60323155D1 (de) Von transthyretin und zur hemmung von transthyretin-fehlfaltung
DE60219917D1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EP1534074A4 (de) Kombinationstherapie zur behandlung von fettleibigkeit
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
DE602004018338D1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
DE60327428D1 (de) Hif hydroxylase-inhibitoren zur anämiebehandlung
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
EA200702212A1 (ru) Способ лечения или профилактики разрушения кости или остеопороза
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
DE60307749D1 (de) Verwendung von Flavonoid-Derivaten zur Behandlung von atopischem Ekzem
ATE318606T1 (de) Zusammenstellungen zur prophylaxe und behandlung von allergien des typus i
DE60327074D1 (de) Fluorobenzamide zur behandlung von alzheimer oder seniler dementia
ATE472329T1 (de) Verwendung der kombination von ciclesonid und antihistaminika zur behandlung von allergischer rhinitis
ATE455553T1 (de) Verwendung von hsp20 zur förderung der wundheilung und/oder zur reduzierung der narbenbildung
DE60200713D1 (de) Zusammensetzung enthaltend getrocknetes Vollei zur Behandlung von Hepatitis
DE50202331D1 (de) Verwendung eines phosphatadsorbers gegen gefässerkrankungen
ATE359088T1 (de) Verwendung von interleukin-18 zur behandlung von uv-assoziierten hautkrankheiten
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
DE602004020741D1 (de) Mittel zur behandlung der allergischen kontaktdermatitis
DE60321377D1 (de) Verwendung von levocetirizin zur behandlung von persistierender allergischer rhinitis
DE60215947D1 (de) Pyridin-2-yl-methylamin-derivate zur behandlung von opiatsucht

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R065 Request for grant of supplementary protection certificate validly filed

Free format text: PRODUCT NAME: WIRKSTOFF DES ARZNEIMITTELS VYNDAQEL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN, EINSCHLIESSLICH DES TAFAMIDIS MEGLUMINSALZES.; REGISTRATION NO/DATE: EU/1/11/717/001 20111116

Spc suppl protection certif: 122012000007

Filing date: 20120117

Expiry date: 20231220

Effective date: 20120220

Free format text: PRODUCT NAME: WIRKSTOFF DES ARZNEIMITTELS VYNDAQEL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN, EINSCHLIESSLICH DES TAFAMIDIS MEGLUMINSALZES.; REGISTRATION NO/DATE: EU/1/11/717/001 20111116

Spc suppl protection certif: 122012000007

Filing date: 20120117

Expiry date: 20231220

Extension date: 20281219

Effective date: 20120220

Free format text: PRODUCT NAME: TAFAMIDIS UND PHARMAZEUTISCH AKZEPTABLE SALZE DAVON, EINSCHLIESSLICH DES TAFAMIDIS-MEGLUMINSALZES; REGISTRATION NO/DATE: EU/1/11/717/001 20111116

Spc suppl protection certif: 122012000007

Filing date: 20120117

Expiry date: 20231220

Extension date: 20261116

Effective date: 20120220

Free format text: PRODUCT NAME: TAFAMIDIS UND PHARMAZEUTISCH AKZEPTABLE SALZE DAVON, EINSCHLIESSLICH DES TAFAMIDIS-MEGLUMINSALZES; REGISTRATION NO/DATE: EU/1/11/717/001 20111116

Spc suppl protection certif: 122012000007

Filing date: 20120117

Expiry date: 20231220

Extension date: 20261118

Effective date: 20120220

R067 Examining division decision granting supplementary protection certificate

Free format text: PRODUCT NAME: WIRKSTOFF DES ARZNEIMITTELS VYNDAQEL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN, EINSCHLIESSLICH DES TAFAMIDIS MEGLUMINSALZES.; REGISTRATION NO/DATE: EU/1/11/717/001 20111116

Spc suppl protection certif: 122012000007

Filing date: 20120117

Expiry date: 20231220

Extension date: 20281219

Free format text: PRODUCT NAME: TAFAMIDIS UND PHARMAZEUTISCH AKZEPTABLE SALZE DAVON, EINSCHLIESSLICH DES TAFAMIDIS-MEGLUMINSALZES; REGISTRATION NO/DATE: EU/1/11/717/001 20111116

Spc suppl protection certif: 122012000007

Filing date: 20120117

Expiry date: 20231220

Extension date: 20261116

Free format text: PRODUCT NAME: TAFAMIDIS UND PHARMAZEUTISCH AKZEPTABLE SALZE DAVON, EINSCHLIESSLICH DES TAFAMIDIS-MEGLUMINSALZES; REGISTRATION NO/DATE: EU/1/11/717/001 20111116

Spc suppl protection certif: 122012000007

Filing date: 20120117

Expiry date: 20231220

Extension date: 20261118

R067 Examining division decision granting supplementary protection certificate

Free format text: PRODUCT NAME: TAFAMIDIS UND PHARMAZEUTISCH AKZEPTABLE SALZE DAVON, EINSCHLIESSLICH DES TAFAMIDIS-MEGLUMINSALZES; REGISTRATION NO/DATE: EU/1/11/717/001 20111116

Spc suppl protection certif: 122012000007

Filing date: 20120117

Expiry date: 20231220

Extension date: 20261116

Free format text: PRODUCT NAME: TAFAMIDIS UND PHARMAZEUTISCH AKZEPTABLE SALZE DAVON, EINSCHLIESSLICH DES TAFAMIDIS-MEGLUMINSALZES; REGISTRATION NO/DATE: EU/1/11/717/001 20111116

Spc suppl protection certif: 122012000007

Filing date: 20120117

Expiry date: 20231220

Extension date: 20261118

R069 Supplementary protection certificate granted

Free format text: PRODUCT NAME: TAFAMIDIS UND PHARMAZEUTISCH AKZEPTABLE SALZE DAVON, EINSCHLIESSLICH DES TAFAMIDIS-MEGLUMINSALZES; REGISTRATION NO/DATE: EU/1/11/717/001 20111116

Spc suppl protection certif: 122012000007

Filing date: 20120117

Expiry date: 20231220

Extension date: 20261116

Effective date: 20130910

Free format text: PRODUCT NAME: TAFAMIDIS UND PHARMAZEUTISCH AKZEPTABLE SALZE DAVON, EINSCHLIESSLICH DES TAFAMIDIS-MEGLUMINSALZES; REGISTRATION NO/DATE: EU/1/11/717/001 20111116

Spc suppl protection certif: 122012000007

Filing date: 20120117

Expiry date: 20231220

Extension date: 20261118

Effective date: 20130910